Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 83,915 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 1Phase 2 Interventional Results available

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT01049945
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
bendamustine hydrochloride, lenalidomide, dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Duarte, California • Jacksonville, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 29, 2026, 6:42 AM EDT
Recruiting Phase 2 Interventional

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

NCT05681195
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
Interventions
Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT), Whole Brain Radiation Therapy (WBRT)
Drug · Procedure · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Biological · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Smoking Cessation Treatment for Adult Women

NCT01422239
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Tailored treatment, Standard Treatment
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 29, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

NCT01790295
View directory record Official record
Conditions
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
Interventions
Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 29, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

NCT00845039
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Vallejo, California • Greenville, North Carolina • Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

NCT01120639
View directory record Official record
Conditions
Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
Interventions
Temozolomide, Stereotactic Radiosurgery (SRS)
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

NCT03337477
View directory record Official record
Conditions
Hyperkalemia
Interventions
Placebo, Sodium Zirconium Cyclosilicate(ZS), Insulin, Glucose
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Montgomery, Alabama • Phoenix, Arizona • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover

NCT01653275
View directory record Official record
Conditions
Osteoporosis, Postmenopausal Bone Loss
Interventions
Mediterranean Diet
Other
Lead sponsor
UConn Health
Other
Eligibility
65 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional

Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy

NCT00537212
View directory record Official record
Conditions
Psoriasis, Weight Loss, Diet
Interventions
The South Beach Diet, The Ornish Diet, Control Group
Other
Lead sponsor
Bagel, Jerry, M.D.
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 1 Interventional

Hyperhidrosis in Patients With Amputations-Botox

NCT03236012
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A (Botox)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Not applicable Interventional Results available

Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients

NCT00692419
View directory record Official record
Conditions
End Stage Renal Disease, Sexual Dysfunction, Physiological, Pain, Depression
Interventions
Symptom management nurse intervention, Feedback intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Acute Renal Failure Trial Network (ATN) Study

NCT00076219
View directory record Official record
Conditions
Acute Renal Failure
Interventions
renal replacement therapy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
22
States / cities
No. Little Rock, Arkansas • San Francisco, California • West Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT02034019
View directory record Official record
Conditions
Post Ocular Surgical Inflammation and Pain
Interventions
Dexamethasone, Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 29, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

NCT03911869
View directory record Official record
Conditions
Brain Metastases
Interventions
encorafenib, binimetinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 29, 2026, 6:42 AM EDT
Terminated Phase 2 Interventional Results available

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

NCT02709083
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia
Interventions
Dasatinib, Imatinib Mesylate, Nilotinib
Drug
Lead sponsor
Emory University
Other
Eligibility
17 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NCT00972283
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
66
States / cities
Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

NCT01321541
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
Interventions
Pixantrone + Rituximab, Gemcitabine + Rituximab
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
51
States / cities
Tucson, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

NCT00068341
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
4
States / cities
Little Rock, Arkansas • Los Angeles, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia

NCT00004905
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, recombinant interferon alfa, cyclophosphamide, cytarabine, etoposide, idarubicin, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 29, 2026, 6:42 AM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Robotic Exoskeleton Assisted Gait Post Stroke

NCT04309305
View directory record Official record
Conditions
CVA, Gait, Hemiplegic
Interventions
EksoGT™, Ekso Bionics, Berkley, CA, USA, Standard of Care, No Intervention
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
21 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 29, 2026, 6:42 AM EDT
Withdrawn Phase 2 Interventional

Development of a Selective ALDH2 Inhibitor to Treat AUD

NCT04311294
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 29, 2026, 6:42 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

NCT01256294
View directory record Official record
Conditions
Renal Transplant
Interventions
Generic Tacrolimus, Branded Tacrolimus
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 29, 2026, 6:42 AM EDT